Anti-METTL3 antibody [EPR18810] - BSA and Azide free,Abcam,AB221795

ab221795 is the carrier-free version of ab195352 . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Compatibility This product is compatible with the Maxpar ® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar ® is a trademark of Fluidigm Canada Inc.

Host

Rabbit

Reactivity

Mouse, Rat, Human

Application

WB, IHC-P, Flow Cyt (Intra), ICC/IF, IP

Platform ID

BAB134234830

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-METTL3 antibody [EPR18810] - BSA and Azide free
Cat. No.AB221795
HostRabbit
IsotypeIgG
ReactivityMouse, Rat, Human
ApplicationWB, IHC-P, Flow Cyt (Intra), ICC/IF, IP
ClonalityMonoclonal
Clone NumberEPR18810
Concentration1.012 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Constituents: PBS
Storage+4°C
Regulatory StatusResearch Use Only

Scientific Background

Target data The METTL3-METTL14 heterodimer forms a N6-methyltransferase complex that methylates adenosine residues at the N(6) position of some RNAs and regulates various processes such as the circadian clock, differentiation of embryonic and hematopoietic stem cells, cortical neurogenesis, response to DNA damage, differentiation of T-cells and primary miRNA processing (PubMed : 22575960, PubMed : 24284625, PubMed : 25719671, PubMed : 25799998, PubMed : 26321680, PubMed : 26593424, PubMed : 27281194, PubMed : 27373337, PubMed : 27627798, PubMed : 28297716, PubMed : 29348140, PubMed : 29506078, PubMed : 30428350, PubMed : 9409616). In the heterodimer formed with METTL14, METTL3 constitutes the catalytic core (PubMed : 27281194, PubMed : 27373337, PubMed : 27627798). N6-methyladenosine (m6A), which takes place at the 5'-[AG]GAC-3' consensus sites of some mRNAs, plays a role in mRNA stability, processing, translation efficiency and editing (PubMed : 22575960, PubMed : 24284625, PubMed : 25719671, PubMed : 25799998, PubMed : 26321680, PubMed : 26593424, PubMed : 28297716, PubMed : 9409616). M6A acts as a key regulator of mRNA stability : methylation is completed upon the release of mRNA into the nucleoplasm and promotes mRNA destabilization and degradation (PubMed : 28637692). In embryonic stem cells (ESCs), m6A methylation of mRNAs encoding key naive pluripotency-promoting transcripts results in transcript destabilization, promoting differentiation of ESCs (By similarity). M6A regulates the length of the circadian clock : acts as an early pace-setter in the circadian loop by putting mRNA production on a fast-track for facilitating nuclear processing, thereby providing an early point of control in setting the dynamics of the feedback loop (By similarity). M6A also regulates circadian regulation of hepatic lipid metabolism (PubMed : 30428350). M6A regulates spermatogonial differentiation and meiosis and is essential for male fertility and spermatogenesis (By similarity). Also required for oogenesis (By similarity). Involved in the response to DNA damage : in response to ultraviolet irradiation, METTL3 rapidly catalyzes the formation of m6A on poly(A) transcripts at DNA damage sites, leading to the recruitment of POLK to DNA damage sites (PubMed : 28297716). M6A is also required for T-cell homeostasis and differentiation : m6A methylation of transcripts of SOCS family members (SOCS1, SOCS3 and CISH) in naive T-cells promotes mRNA destabilization and degradation, promoting T-cell differentiation (By similarity). Inhibits the type I interferon response by mediating m6A methylation of IFNB (PubMed : 30559377). M6A also takes place in other RNA molecules, such as primary miRNA (pri-miRNAs) (PubMed : 25799998). Mediates m6A methylation of Xist RNA, thereby participating in random X inactivation : m6A methylation of Xist leads to target YTHDC1 reader on Xist and promote transcription repression activity of Xist (PubMed : 27602518). M6A also regulates cortical neurogenesis : m6A methylation of transcripts related to transcription factors, neural stem cells, the cell cycle and neuronal differentiation during brain development promotes their destabilization and decay, promoting differentiation of radial glial cells (By similarity). METTL3 mediates methylation of pri-miRNAs, marking them for recognition and processing by DGCR8 (PubMed : 25799998). Acts as a positive regulator of mRNA translation independently of the methyltransferase activity : promotes translation by interacting with the translation initiation machinery in the cytoplasm (PubMed : 27117702). Its overexpression in a number of cancer cells suggests that it may participate in cancer cell proliferation by promoting mRNA translation (PubMed : 27117702). During human coronavirus SARS-CoV-2 infection, adds m6A modifications in SARS-CoV-2 RNA leading to decreased RIGI binding and subsequently dampening the sensing and activation of innate immune responses (PubMed : 33961823). See full target information METTL3

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.